And from the ATHE 30/6/2020 annual report filing page 2
"...as we expand our research and development and pre-clinical activities and commence clinical trials of our product candidates that includes ATH434 for Parkinsonian diseases, prospectively PBT2 for alternative indications and the development of other compounds"
PBT2 further development!, page-8
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $200 | 66.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 75238609 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 4967441 | 3 |
View Market Depth
| Last trade - 10.00am 10/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |